Amneal Pharmaceuticals, Inc. (AMRX) is a publicly traded company in the Healthcare sector, operating within the Drug Manufacturers - Specialty & Generic industry. The company is headquartered in Bridgewater, NJ, United States. The current CEO is Chirag K. Patel.
AMRX has IPO date of 2018-05-07, 8,300 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $4.13B.
Amneal Pharmaceuticals, Inc. is a diversified pharmaceutical company that develops, manufactures, and distributes generic and specialty pharmaceutical products across multiple dosage forms and therapeutic areas. The company operates through three segments: Generics, which produces complex oral solids, injectables, ophthalmics, and other formulations; Specialty, which markets branded products for central nervous system disorders, endocrinology, and parasitic infections including brands like Rytary and Unithroid; and AvKARE, which supplies pharmaceuticals and medical products to government agencies and the Department of Defense. Amneal serves customers through wholesalers, distributors, hospitals, and retail pharmacies across the United States, India, Ireland, and internationally. Founded in 2002 and headquartered in Bridgewater, New Jersey, the company has established itself as a significant player in both the generic and specialty pharmaceutical markets.
